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ABSTRACT 
Objective  
ABCC8 mutations cause neonatal diabetes that can be transient (TNDM) or less commonly permanent 
(PNDM); ~90% individuals can be treated with oral sulfonylureas instead of insulin.  Previous studies 
suggested that people with ABCC8-PNDM require lower sulfonylurea doses and have milder 
neurological features than those with KCNJ11-PNDM.  However, these studies were short-term and 
included combinations of permanent and transient forms of ABCC8-NDM.  We aimed to assess the 
long-term glycemic and neurological outcomes in sulfonylurea-treated ABCC8-PNDM.   
Research Design and Methods  
We studied all 24 individuals with ABCC8-PNDM diagnosed in the UK, Italy, France or USA know 
to transfer from insulin to sulfonylureas before May 2010.  Data on glycemic control, sulfonylurea 
dose, adverse effects including hypoglycemia, and neurological features were analysed using non-
parametric statistical methods.   
Results  
Long-term data were obtained for 21/24 individuals (median follow-up 10.0 (4.1-13.2) years).  18/21 
remained on sulfonylureas without insulin at most recent follow-up.  Glycemic control improved on 
sulfonylureas (pre-sulfonylurea vs 1-year post-transfer HbA1c 7.2% vs 5.7%, p=0.0004) and 
remained excellent long-term (1-year vs. 10-year HbA1c 5.7% vs. 6.5%, p=0.04), n=16.  Relatively 
high doses were used (1-year vs 10-year dose 0.37 vs 0.25mg/kg/day glyburide, p=0.50), without any 
severe hypoglycemia.  Neurological features were report d in 13/21 individuals: these improved 
following sulfonylurea transfer in 7/13.  The commonest features were learning difficulties (52%), 
developmental delay (48%), and ADHD (38%). 
Conclusions  
Sulfonylurea treatment of ABCC8-PNDM results in excellent long-term glycemic contrl.  Overt 
neurological features frequently occur and may improve with sulfonylureas, supporting early, rapid 
genetic testing to guide appropriate treatment and neurodevelopmental assessment.   
Introduction 
The ABCC8 gene encodes the SUR1 subunit of the pancreatic ATP-sensitive potassium (KATP) 
channel (1).  SUR1 forms hetero-octameric complexes with Kir6.2, encoded by the KCNJ11 gene (2).  
Mutations in KATP channel genes are the commonest cause of neonatal diabetes in non-
consanguineous populations, with ~15-20% due to ABCC8 mutations and ~25-30% due to KCNJ11 
mutations (3).  Neonatal diabetes typically occurs in the first 6 months of life and can be permanent 
(PNDM), where diabetes persists lifelong, or transie t (TNDM), where there is a period of remission 
of diabetes after 6-12 months followed by relapse in adolescence or early adulthood (4).  ABCC8 
mutations cause TNDM in ~80% of cases and PNDM in ~20% cases; the opposite pattern is observed 
with KCNJ11 mutations, which most frequently result in PNDM (5).   
ABCC8 and KCNJ11 mutations cause neonatal diabetes by preventing closure of pancreatic KATP 
channels in response to rising glucose (6, 7).  This results in insulin deficiency, which historically 
required treatment with replacement doses of insuli.  However, in ~90% of affected individuals 
sulfonylurea treatment can bypass the genetic defect by binding SUR1 and closing pancreatic KATP 
channels, promoting secretion of endogenous insulin and allowing patients to stop insulin injections 
and achieve excellent glycemic control and better quality of life (8-10).  Sulfonylureas are the 
optimum treatment for KCNJ11 PNDM long-term; in those patients who successfully transfer from 
insulin to sulfonylureas, metabolic control is maint ed in >90% for at least 10 years with no serious 
adverse effects despite doses being ~2-10 times higher than those recommended in Type 2 Diabetes 
(T2D) (11).  Short-term studies have suggested that lower doses of sulfonylurea are required to treat 
ABCC8-NDM in comparison to KCNJ11-NDM (9, 12).  However, many previous studies contained 
both individuals with ABCC8-PNDM and ABCC8-TNDM, which have different clinical courses and 
treatment requirements (5, 6, 9).  No study has assessed the long-term outcomes of sulfonylurea 
treatment specifically in ABCC8-PNDM. 
ABCC8 and KCNJ11 are both expressed in the brain as well as the pancre s (13, 14), therefore in 
addition to diabetes, central nervous system (CNS) features are observed in individuals with KATP 
channel mutations.  These vary from the severe developmental delay, epilepsy and neonatal diabetes 
(DEND) syndrome, to mild neuropsychological impairments detectable only on detailed 
neuropsychomotor testing (5, 15).  In KCNJ11-PNDM, there is some correlation between the position 
of the variant in the protein and the clinical features.  In contrast, in ABCC8-PNDM genotype-
phenotype relationships appear less distinct (16).  In around half of individuals with KCNJ11-PNDM, 
sulfonylurea treatment results in partial improvement of the neurological features, which is thought to 
be due to the action of glyburide on KATP channels in the brain (11, 17). 
Observational studies have suggested that the CNS features are not as common and /or severe in 
individuals with ABCC8 mutations (5, 6, 18, 19), in comparison to those with KCNJ11 mutations.  
However, as discussed above, previous research findings are based on cohorts containing both 
individuals with ABCC8-PNDM and ABCC8-TNDM.  In addition, the majority of studies 
investigating the neurodevelopmental features associated with KATP channel mutations and the 
response of these features to sulfonylurea treatment have focused on patients with KCNJ11-PNDM.   
Research relating to the CNS features in individuals with ABCC8-PNDM and the impact of long-term 
sulfonylurea treatment on both glycemic and neurological outcomes is crucial to establish and to 
inform clinical guidelines for this specific subtype.   
 
Aim 
To assess the long-term glycemic and neurological response to sulfonylureas in an international 
cohort of patients with PNDM due to ABCC8 mutations.  
 
Research Design and Methods 
Patient cohort 
Patients with a molecular genetic diagnosis of PNDM due to mutations in the ABCC8 gene 
(NM_001287174.1) confirmed in laboratories in Exeter (UK), Rome (Italy), Paris (France) and 
Chicago (USA) known to transfer to sulfonylureas prior to 30th April 2010 with no period of 
remission of their diabetes were eligible for inclusion in the study (n=24).  Three patients were lost t  
follow-up in the first year after sulfonylurea transfer and were therefore excluded, leaving 21 patients 
with sufficient follow-up data (>4 years) for further analyses.   
The study was conducted in accordance with the Declaration of Helsinki as revised in 2000.  Patient 
data was collected during routine clinical care or through research surveys and was anonymised for 
use in the study.  The study is registered with ClinicalTrials.gov, number NCT02624830. 
Data Collection  
Data were collected from the clinical records of participating patients or through research surveys 
completed by the participant or their carer(s).  Data on glycemic control, sulfonylurea dose, and 
hypoglycemia, were collected before and after transfer from insulin to sulfonylureas, and annually 
until the most recent clinic follow-up. Clinicians and participants were asked to report side-effects or 
diabetes complications that occurred at any time point during the follow-up and if so to provide 
details about these.  
Data on neurological features were collected before transfer from insulin to sulfonylureas, and after 
transfer at most recent follow-up.  Clinicians or pa ticipants were specifically asked about the 
presence of developmental delay (DD), learning difficulties (LD), attention-deficit hyperactivity 
disorder (ADHD), epilepsy, sleep problems, muscle weakness, anxiety, autism, and spasticity as well 
as ‘other’ difficulties (11), and whether these features (if present) had improved on transfer to 
sulfonylureas. 
Statistical Analysis 
Data were analysed in Stata 16.0 using non-parametric statistical methods.  Clinical characteristics of 
patients who remained on sulfonylurea alone were compared with those who required permanent 
reintroduction of insulin using the Mann-Whitney test for continuous data and 2-sample test of 
proportions for categorical data.  For those patients who remained on sulfonylurea alone for the 
duration of the follow-up, paired data on metabolic control (HbA1c) and sulfonylurea dose were 
compared using the Wilcoxon signed-rank test.  For th se individuals with annual data available for 
>50% of time points, longitudinal trends in HbA1c and sulfonylurea dose were plotted.  Missing data 
were imputed as previously described (11).   
Individuals who required insulin therapy only transiently or who were prescribed any other oral anti-
diabetic medication at any point in the follow-up were classified in the sulfonylurea only group.  One 
individual (mutation, L1148R/R1380C) transferred from insulin to sulfonylureas twice aged 18 
months (for 4 years) and again aged 26 years.  His follow-up data relates to the second sulfonylurea 
transfer as no data were available after the first transfer 35 years ago.  
For sulfonylureas other than glyburide, doses were converted to glyburide equivalent using percentage 
of maximum glibenclamide (glyburide) dose as per th British National Formulary (BNF) (20).   Data 
are presented as median (range) unless stated otherwise.  For all analyses, a p-value of less than 0.05




Clinical characteristics of the patients included in the study are shown in Tables 1 and 2.     
Duration of follow-up 
Median duration of follow-up was 10.0 (4.1-13.2) years, comprising a total of 205 patient years.   
Sulfonylurea efficacy 
At most recent follow-up, 18/21 (86%) patients remained on sulfonylurea therapy without insulin.  
For all three individuals who had restarted insulin, clinicians reported problems with adherence with 
prescribed medication and/or periods of loss to clinic/hospital follow-up.  Clinical characteristics were 
similar between the individuals who remained on sulfonylureas vs. those who required reintroduction 
of insulin (Table 1).   
Type of sulfonylurea prescribed 
All patients who remained independent of insulin at most recent follow-up were prescribed glyburide 
for the duration of the study.  One patient was prescribed glyburide at initial transfer from insulin a d 
was switched to tolbutamide at day 45 post-transfer (21); this individual subsequently required 
reintroduction of insulin therapy having stopped sulfonylurea treatment whilst lost to hospital follow-
up.     
Metabolic control and sulfonylurea dose 
Paired data on pre-transfer HbA1c and HbA1c and sulfonylurea dose at year 1 (median 0.97, range 
0.27-1.76 years) and year 10 (median 9.8, range 6.1-12.5 years) were available for 16 individuals.  In 
these individuals, glycemic control improved on transfer to sulfonylurea [pre-transfer vs 1-year 
HbA1c 7.2 (5.3-9.5) vs 5.7 (5.0-7.3)% (55 (34-80) vs. 39 (31-56) mmol/mol), p=0.0004] and 
remained excellent at long-term follow-up [1-year vs. 10-year HbA1c 5.7 (5.0-7.3) vs. 6.5 (5.3-7.7)% 
(39 (31-56) vs. 48 (34-61) mmol/mol), p=0.04], figure 1a.  High doses of sulfonylurea were used in 
most individuals [1-year vs 10-year dose 0.37 (0.01-1.25) vs 0.25 (0.03-1.30) mg/kg/glyburide, 
p=0.50], figure 1b.  Only 3 individuals required doses under 0.1mg/kg/day glyburide at most recent 
follow-up.  In 11 individuals who had sufficient annual data available, there was a gradual reduction 
in median sulfonylurea dose per kilogram of body weight over time despite relatively stable glycemic 
control, figure S1.   
Side-effects 
Diarrhea was reported in two individuals.  One individual was diagnosed with irritable bowel 
syndrome (IBS).  The second individual, previously reported by Codner et al, experienced transient 
diarrhea on glyburide; this stopped on switching to tolbutamide (21).  No other adverse effects of 
sulfonylurea therapy were reported.   
Hypoglycemia  
There were no episodes of severe hypoglycemia, defined as losing consciousness or having seizures 
(22), reported over the course of the follow-up in atients treated with sulfonylurea alone.  In one 
individual on glyburide treatment, an episode was repo ted whereby the blood glucose remained 
<4.0mmol/l even after treatment with fruit juice and third party assistance was required.  Another 
individual switched treatment from glyburide to tolbutamide (see above), due to episodes of 
asymptomatic hypoglycemia on glyburide treatment; these settled on tolbutamide (21).   
Diabetes Complications 
Microvascular complications occurred in 2 individuals; one had microalbuminuria, and one had 
microalbuminuria (normotensive) and proliferative retinopathy requiring intravitreal injections and 
photocoagulation, as well as mildly elevated LDL trea ed with a statin medication.  These individuals 
transferred to sulfonylureas aged 10 years and 26 years (after a short period of sulfonylurea treatment 
as a child - see above).  There were no macrovascular omplications reported over the period of 
follow-up.   
Body Mass Index (BMI) 
In 10 individuals who remained independent of insulin and had paired height and weight data 
available, BMI remained normal [BMI standard deviation score (SDS) pre-sulfonylurea treatment -
0.13(-0.85-1.44) and at most recent follow-up on sulfonylureas -0.29 (-0.99-0.94), p=0.23].  
Central Nervous System (CNS) Features 
13/21 (62%) patients were reported to have CNS featur s before and after transfer to sulfonylurea, 
figure 3a and Table S1.  The commonest features at mos recent follow-up were developmental delay 
(DD) in 48%, learning difficulties (LD) in 52% and attention deficit hyperactivity disorder (ADHD) 
in 38%.  Co-morbidity was common: 11 individuals had 3 or more specific CNS features together.  .In 
five individuals, seizures were or may have been a result of factors other than the genetic mutation 
(Table S2).   
In 7/13 (54%) there was some improvement (n=5) or complete resolution (n=2) noted in neurological 
features on starting sulfonylureas, figure 3a and Table S1.  In the 2 patients whose neurological 
features completely resolved, both had DD pre-transfer (with LD in one case) but subsequently 
attained a developmental level expected for their age.   
All 3 patients who required reintroduction of insulin treatment had neurological features (Table 1); 
there was improvement in the EEG background in one of these patients following initial transfer from 
insulin onto sulfonylureas.  Age at transfer to sulfonylureas was similar in those patients with and 
without neurological features at most recent follow-up [6.6 (0.5-18.2 vs. 8.4 (0.9-26.0) years, p=0.53]. 
   
 
Discussion / Conclusions 
In summary, in our 10-year study of 21 individuals with sulfonylurea-treated ABCC8-PNDM, 86% 
remained independent of insulin at their most recent follow-up.  Furthermore, glycemic control was 
maintained on relatively high doses of sulfonylurea, without any reports of severe hypoglycemia or 
side effects.  A large proportion of the cohort (62%) had overt neurological features both prior to 
sulfonylurea transfer and at most recent follow-up, and co-morbidity was common.  There was partial 
improvement in some CNS features in just over half of individuals following transfer to sulfonylurea 
therapy.   
The excellent long-term outcomes in sulfonylurea-treated ABCC8-PNDM are similar to those 
observed in KCNJ11-PNDM, Table S3 (11).  Our data do not support the suggestion from previous 
studies that lower doses of sulfonylurea may be requi d in people with ABBC8 mutations in 
comparison to those with KCNJ11 mutations (9).  This may be due at least in part to the inclusion of 
patients with transient and permanent forms of ABCC8-NDM in earlier cohort studies (9) and a lower 
sulfonylurea dose requirement in the patients with TNDM (23).  In this study, behavioural and / or 
social factors are likely to explain the deterioration in glycemic control in the 3 individuals with 
ABCC8-PNDM who required reintroduction of insulin. 
We have shown that overt CNS features in ABCC8-PNDM occur with relatively high frequency and 
that co-morbidity is common, in contrast with previous studies that included cohorts of patients with 
ABCC8-TNDM and PNDM (5, 6, 9).  Indeed, the frequency andnature of CNS features in ABCC8-
PNDM is similar to that observed in KCNJ11-PNDM, Table S3 (11), with the exception of autism 
which has been more frequently reported in KCNJ11-PNDM (11, 24, 25).   
The partial improvement in neurological features in 7/13 individuals on transferring to sulfonylureas 
is consistent with previous cases and suggests that the drugs may improve neurological function in 
some patients with ABCC8-PNDM, although a randomised controlled trial would be required to prove 
this definitively.  It has been suggested the improvement in neurological features is greater the earlier 
sulfonylureas are started (17, 26), reflecting greater neuroplasticity at a younger age with a so-called 
‘sensitive period’ occurring within the first 6 months of life (27).  In our cohort, only 2 patients 
transferred under the age of 1 year and none transferred under the age of 6 months, therefore this 
crucial sensitive period for the action of sulfonylureas in the brain may have been missed.  Studies in 
rats have suggested that glyburide is actively transported out of the brain (28); this may make it 
difficult to achieve therapeutic concentrations of the drug in the cerebrospinal fluid (CSF).  As a 
result, recommended doses of glyburide in patients with KATP channel-related PNDM and severe 
neurological features are higher (at least ~1mg/kg/day) (29).  Of those individuals who remained 
independent of insulin in our cohort, only 2 were on a dose this high at their most recent follow-up.  
Furthermore, there was a tendency for glyburide doses to fall over time, which may reflect lack of 
adjustment of total daily doses according to increases in body weight as children grow.  This may also
explain the slightly higher HbA1c at most recent follow-up when compared with year 1.  
These factors emphasise the need for early genetic tes ng and identification of all patients with 
ABCC8-PNDM.  Prompt genetic diagnosis facilitates early transfer to sulfonylureas, as well as 
systematic screening of all affected individuals for neurodevelopmental features at diagnosis and 
follow-up, and provision of appropriate support.  Clinicians should consider higher doses of 
sulfonylureas if neurological features are present.  They should also regularly adjust total daily dose to 
maintain the same dose per kilogram of body weight over time, thereby optimising treatment for both 
glycemia and neurological features. 
Variable modes of inheritance are observed in our chort; there is a mixture of dominant heterozygous 
ABCC8 mutations (n=11) as well as compound heterozygous (n=7) and homozygous variants (n=3), 
in keeping with previous studies (30).  This has impl cations for genetic counseling in relation to 
recurrence risk and carrier status in future offspring, which will be different for dominant vs recessive 
inheritance.   In this study, there were no differences in long-term outcomes between individuals with 
dominant heterozygous vs recessive (homozygous and compound heterozygous) mutations (Table 2).  
However, our study was not designed to address this que tion, and research in larger cohorts will be 
required to investigate the impact of mode of inheritance on clinical outcomes in ABCC8-PNDM.  An 
additional limitation is the wide range of specific genetic variants included, which prevents the 
identification of strong genotype-phenotype relationships.   
Finally, neurological features were not screened for systematically via repeated assessments in one 
center over the course of the follow-up, and comprehensive neuropsychological testing was not done 
as part of this study.  Therefore, there is likely to be variable ascertainment and / or reporting of CNS 
features based on what was recorded in the clinical otes.  This might result in an underestimation of 
the extent of neurological involvement in affected in ividuals.  It is not possible to fully distinguish 
the relative contributions of mutant KATP channels in the brain and other factors to the neurological 
features reported (Table S2).  It is likely that in at least some individuals the neurological features will 
be due to a combination of different etiologies.  Despite these limitations, this is the first study to 
assess the long-term treatment response and CNS features in an international cohort of patients with 
ABCC8-PNDM.  
Further research in larger cohorts of individuals with ABCC8 mutations will be required to investigate 
in more detail the CNS phenotype, genotype-phenotype relationships, and factors influencing the 
glycemic response to sulfonylureas e.g. specific physiological states such as puberty and pregnancy.     
Conclusions 
We have shown for the first time that sulfonylurea therapy is effective and safe long-term for people 
with PNDM due to ABCC8 mutations, with excellent glycemic control maintained over 10 years 
without severe hypoglycemia or side effects, despit relatively high doses in most patients.  
Importantly, affected individuals frequently have multiple overt CNS features, which, in some, may 
partly improve with sulfonylureas.  Rapid genetic diagnosis is crucial to facilitate early initiation f 
precision therapy with sulfonylureas in ABCC8-PNDM, and enable prompt identification of 
neurodevelopmental features and provision of appropriate support for affected families. 
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Figure Legends 
Figure 1.  Part A: HbA1c pre-sulfonylurea transfer, at year 1 and at most recent follow-up in 16 
patients with data available at all 3 time points.  Circles represent individuals and black horizontal 
lines represent group medians.  Part B: Sulfonylurea dose at year 1 and at most recent follow-up in 16 
patients included in Figure 1A.  Circles represent individuals and black horizontal lines represent 
group medians. 
Figure 2: Number of patients with ABCC8-PNDM with neurological features relative to sulfonylurea 
transfer.  CNS = central nervous system.   
 
Online Supplemental Material 
Supplementary Appendix.  Neonatal diabetes international collaboration. 
Supplementary Table S1.  Neurological features present before and after transfer to sulfonylureas, and 
features that improved on SU transfer.   
Supplementary Table S2.  Clinical details of patients i  whom seizures / epilepsy may have been 
attributable to factors other than the genetic mutation. 
Supplementary Table S3.  Comparison of long-term outcomes in individuals with mutations in the 
KCNJ11 and ABCC8 genes. 
Figure S1. HbA1c and sulfonylurea dose in 11 patients with at least 50% of annual longitudinal data 
available for both variables.  Data are presented as median (interquartile range). Missing data were 
imputed as previously described (11). 
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Clinical feature On SU without insulin at most recent follow-up 
(n=18) 
On insulin with or without SU at most 
recent follow-up (n=3) 
P-value (on SU 
vs on insulin) 
Genotype E208K/Y263D, V86G/N, D212I/N, P45L/G1401R, 
V86A/N, L1295F/N, T229I/V1532L, L225P/N, 
L135P/N, 2 E382K/E382K, L213R/N, 
R168C/G1256S, V215A/V215A, E208K/D1472N, 
V324M/W688R, L213P/N, L1148R/R1380C 
D209E/N, R1380L/N, Q211K/N N/A 
N male (%) 10 (56) 0 (0) 0.07 
Birth weight (g) 2750 (1510-3402) (n=16) 2700 (2400-2700) (n=3) 0.62 
Age at diagnosis (weeks) 7.5 (1.0-47.0) (n=18) 6.0 (5 -17.0) (n=3) 1.00 
Age at transfer to SU (years) 7.6 (0.5-26.0) (n=18) 5.8 (2.8-9.4) (n=3) 0.46 
Current age (years) 21 (11-36) (n=18) 19 (16-22) (n=3) 0.58 
Pre-SU HbA1c (%) 7.5 (5.3-9.5) (n=18) 6.8 (6.7-7.2) (n=3) 0.52 
Pre-SU HbA1c (mmol/mol) 58 (34-80) (n=18) 51 (50-55) (n=3) 0.52 
Year 1 HbA1c (%) 5.7 (5.0-7.3) (n=16) 6.8 (6.7-6.9) (n=2) 0.13 
Year 1 HbA1c (mmol/mol) 39 (31-56) (n=16) 51 (50-52) (n=2) 0.13 
Most recent HbA1c (%) 6.7 (5.3-10.1) (n=18) 9.8 (5.9-10.3) (n=3) 0.17 
Most recent HbA1c (mmol/mol) 50 (34-87) (n=18) 84 (41-89) (n=3) 0.17 
Year 1 SU dose (mg/kg/day glyburide) 0.37 (0.01-1.25) (n=16) 0.03 (0.01-0.04) (n=2) 0.05 
Most recent SU dose (mg/kg/day glyburide) 0.35 (0.03 – 1.30) (n=18) 0.74 (0.02-1.45) (n=2) 1.00 
Neurological features (any) 10 (56) 3 (100) 0.15 
Pre-SU BMI SDS (kg/m2) -0.13 (-0.85-1.44) (n=10) -0.53 (-1.68- -0.26) (n=3) 0.10 
Most recent BMI SDS (kg/m2) -0.75 (-3.69 – 1.28) (n=13) -1.34 (-1.94 - -0.24) (n=3) 0.19 
 
Table 1.  Clinical features of whole cohort, including all data available at all time points.  Data are p esented as median (range). Year 1 is median duration 0.97 
(0.27-1.76 years); data closest to one year used.  Most recent duration for sulfonylurea dose and HbA1c median 10.0 (4.1-13.2) years.  Most recent duration for 
BMI 9.8 (4.6-13.2) years (most recent time point at which both height and weight data available).  N is different for each variable due to differences in amount 
of available data.  Most recent sulfonylurea dose is different to that reported in the results section due to paired values for sulfonylurea dose and HbA1c at all 
time points being unavailable for 3 individuals included in the table.  SU = sulfonylurea, BMI = body mass index, SDS = standard deviation score.  SU = 
sulfonylurea, BMI = body mass index, SDS = standard deviation score. 
 
Table 2.  Clinical features of individuals with dominantly vs recessively inherited variants in the ABCC8 gene.  Data are presented as median (range).  N is 
different for each variable due to differences in amount of available data.  SU = sulfonylurea, N = number. 
 
Clinical feature Dominant heterozygous (n=11) Recessive (compound heterozygous / homozygous) (n=10) P-value  
Genotype D209E/N, D212I/N, L1295F/N, L135P/N, 
L213P/N, L213R/N, L225P/N, Q211K/N, 
R1380L/N, V86G/N, V86A/N  
2 E382K/E382K, E208K/D1472N, E208K/Y263D, 
L1148R/R1380C, P45L/G1401R, R168C/G1256S, 
T229I/V1532L, V215A/V215A, V324M/W688R  
N/A 
Duration of follow-up (years) 11.2 (7.9-13.2) 9.1 (4.1-12.3) 0.02 
N male (%) 4/11 (36) 6/10 (60) 0.27 
Birth weight (g) 2700 (2100-3065) (n=9) 2750 (1510-3402) (n=10) 0.76 
Age at diagnosis (weeks) 6 (2-17) (n=11) 11 (1-47) (n=10) 0.48 
Age at transfer to SU (years) 5.8 (1.9-12.0) (n=11) 10.3 (0.5-26.0) (n=10) 0.12 
Current age (years) 19 (15-23) (n=11) 22.5 (11-36) (n=10) 0.08 
Pre-SU HbA1c (%) 6.7 (5.3-7.9) (n=11) 8.1 (5.8-9.5) (n=10) 0.001 
Pre-SU HbA1c (mmol/mol) 50 (34-63) (n=11) 65 (40-80) (n=10) 0.001 
Year 1 HbA1c (%) 6.0 (5.0-6.9) (n=10) 5.7 (5.0-7.3) (n=8) 0.92 
Year 1 HbA1c (mmol/mol) 42 (31-52) (n=10) 39 (31-56) (n=8) 0.92 
Most recent HbA1c (%) 7.0 (5.3-10.3) (n=11) 6.3 (5.3-10.1) (n=10) 0.32 
Most recent HbA1c (mmol/mol) 53 (34-89) (n=11) 45 (34-87) (n=10) 0.32 
Year 1 SU dose (mg/kg/day 
glyburide) 
0.09 (0.01-1.25) (n=10) 0.50 (0.17-1.11) (n=8) 0.08 
Most recent SU dose (mg/kg/day 
glyburide) 
0.36 (0.02-1.45) (n=10) 0.35 (0.10-1.30) (n=10) 0.67 
N on insulin at recent follow-up 3/11 (27) 0/10 (0) 0.08 
N with neurological features any at 
most recent visit (%) 



















CNS feature  Pre SU transfer (n) Post SU transfer (n) Post transfer only (n) Improvement on SU (n) 
Any  13 13 0 7 
DD 10 10 1 3 
LD 7 11 2 1 
ADHD  6 8 2 1 
Epilepsy 4 3 2 2** 
Muscle weakness 2 2 0 0 
Anxiety 2 2 0 0 
Sleep problems 2 2 1 0 
Spasticity 2 2 0 0 
Autism 0 0 0 N/A 
Other* 5 4 0 1*** 
 
Supplementary Table S1.  Neurological features present before and after transfer to sulfonylureas, and features that improved on SU transfer   
*‘Other’ CNS features prior to sulfonylurea transfer in addition to the specific features listed consisted of obsessive-compulsive disorder (OCD) with mild 
Tourette’s, encopresis, hypertonia, hypotonia and an abnormal electroencephalogram (EEG) (in the absence of a diagnosis of epilepsy).  These features were 
also present after sulfonylurea transfer with the exception of hypotonia (but not known if this was teted).   
**both individuals had seizures at time of diagnosis only which may have been attributable to cerebral oedema (Table S2)  
individuals treated with anti-epileptic medication not included as ‘improved’ (Table S2)   
***improved background on EEG  












Clinical history Other neurological 
features present in 
addition to seizures / 
epilepsy 
Neurological features improved on 
transfer to SU 
Individuals in whom metabolic disturbance at diagnosis may have contributed to seizures  
P45L/G1401R 6 8 Diabetic ketoacidosis at 6 weeks of age with 
severe dehydration, reduced consciousness, 
opisthotonus and partial seizures - diagnosed with 
cerebral edema (31) 
Muscle weakness, 
hypertonia, spasticity, 
DD, LD, and sleep 
problems 
Improvements in sleep, speech, 
concentration and schoolwork noted by 
parents and teachers.  No epilepsy at most 
recent follow-up. 
V215A/V215A 9 0.5 Focal seizures around time of diagnosis: in left 
arm 2 days before admission and in left arm and 
leg 2 days after admission 
DD (mild), LD (mild) No seizures since 2 months of age but on 
antiepileptic drugs.  Other features (DD / 
LD) identified only after SU transfer. 
V86G/N 5 3 Seizures only at time of diagnosis: none si ce. DD, LD, ADHD, 
anxiety 
Slight improvement.  No anxiety post SU 
transfer and no further seizures.  Main 
problem currently is speech delay / 
difficulties at school. 
Individuals in whom seizures are attributable to another (non-metabolic) cause  
L1295F/N 12 6 One seizure due to starting treatment with 
dexmethylphenidate for ADHD (no further 
seizures on stopping drug) 
DD, LD, ADHD, 
muscle weakness 
No change. 
L135P/N 6 10 Viral meningoencephalitis at 6 weeks of age, 
treated with Depakine 200-300mg at clinic 
follow-up prior to SU transfer 
Spastic paraplegia, DD, 
LD, sleep problems 
No change.  Epilepsy not reported at recent 
follow-up but has had treatment with 
antiepileptic drugs 
 
Supplementary Table S2.  Clinical details of patients in whom seizures / epilepsy may have been attributable to factors other than the genetic 
mutation.  SU = sulfonylurea, DD = developmental delay, LD = learning difficulties, ADHD = attention deficit hyperactivity disorder 
Outcome on SU treatment ABCC8-PNDM (n=21) KCNJ11-PNDM (n=81) 
Patients independent of insulin at 10 years (%) 86 93 
Median HbA1c at 10 years - paired (%) 6.5 (n=16) 6.4 (n=64) 
Median SU dose required at 10 years - paired (mg/kg/day glyburide)   0.25 (n=16) 0.23 (n=64) 
Median BMI at 10 years SDS (kg/m2) -0.75 (n=13) -0.22 (n=72) 
Frequency of neurological features at 10 years (%) 62 (n=21) 64 (n=81) 
Improvement in neurological features after SU transfer (%) 54 (n=13) 47 (n=38) 
Number of episodes of severe hypoglycemia on SU only ver 10 years 0 (n=18) 0 (n=75) 
Frequency of side effects (%) 11 (n=18) 14 (n=81) 
Frequency of diabetes complications (%) 11 (n=18) 9 (n=81) 
 
Supplementary Table S3.  Comparison of long-term outcomes in individuals with mutations in the KCNJ11 and ABCC8 genes.  
Comparative data on KCNJ11-PNDM taken from Bowman et al Lancet D&E 2018 (11)  SU = sulfonylurea,  PNDM = permanent neonatal diabetes mellitus,  
BMI = body mass index, SDS = standard deviation score 
 
 
 
 
 
 
 
 
 
 
 
